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Background: Quality of life (QOL) and its measurement in cancer patients is becoming increasingly important.
Breast cancer diagnosis and treatment are often associated with psychological distress and reduced QoL. In
Arabic-speaking countries, QoL of patients with cancer is inadequately studied.
The aim of this study was to test the reliability and validity of the Moroccan Arabic version of the European
Organization for Research and Treatment of Cancer (EORTC) Breast Cancer-Specific Quality of Life Questionnaire
(QLQ-BR23).
Methods: After translation and cross-cultural adaptation, the questionnaire was tested on breast cancer patients.
The participants’ number for the test and the retest were 105 and 37 respectively. Internal consistency was tested
using Cronbach’s alpha coefficient (α), the test-retest reliability using intraclass correlation coefficients (ICC).
Construct validity was assessed by examining item-convergent and divergent validity.
Results: The questionnaire was administered to 105 patients. The mean age of patients was 48 years (SD: 16),
62.9% were married. 68.6% of all participants lived in urban area.
The average time to complete the QLQ- BR23 was 15 min. Cronbach’s alpha coefficient, were all >0.7, with the
exception of breast symptoms and arm symptoms. All items exceeded the 0.4 criterion for convergent validity
except item 20 and 23 related to pain and skin problems in the affected breast respectively.
Conclusion: In general, the findings of this study indicated that the Moroccan Arabic version of the EORTC
QLQ-BR23 is a reliable and valid supplementary measure of the QOL in breast cancer patients and can be used in
clinical trials and studies of outcome research in oncology.
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Worldwide, breast cancer is the most common malig-
nancy diagnosed in women, the second most common
type of cancer after lung cancer (10.4% of all cancer in-
cidence, both sexes counted) and the fifth most com-
mon cause of cancer death. In 2008, breast cancer
caused 458 000 deaths worldwide [1,2]. Breast cancer is
the most frequent type of cancer among women in
Morocco (33.4%) [3].
Today, Health-related quality of life (HRQOL) is now
considered an important endpoint in cancer clinical trials.
Although there has been considerable researches on the
quality of life (QOL) of women with breast cancer [4],
the results may not be significantly affecting clinical de-
cision – making because the clinical significance of find-
ings is not specified [5,6]. More studies are therefore
needed to make QOL assessment feasible, understand-
able and scientifically viable in oncology researches and
practices [6]. In particular, HRQOL assessments in on-
cology facilitate doctor –patient communication, they
point to areas where patients may experience serious prob-
lems, they can be used as diagnostic tools for problem- ori-
ented follow – up care, and the data are strong predictors
of survival [7,8].
The European Organization for Research and Treatment
of Cancer (EORTC) has developed several questionnaires
to assess QoL. In assessing quality of life in cancer patients,
it is recommended to use a cancer-specific questionnaire
as a general measure of quality of life (e.g. the EORTC
QLQ-C30) [9] plus site-specific modules (e.g. breast can-
cer specific or gastric cancer specific). Thus, for instance
the EORTC, in addition to core cancer quality of life ques-
tionnaire, has developed several site-specific question-
naires including one for breast cancer (QLQ-BR23) [10] in
order to collect more relevant patient-reported outcomes
in studying quality of life in this group of cancer patients.
The English-language versions of these questionnaires
were successfully tested [10], it has been found to be reli-
able and valid in diverse cultures, including, the United
Arab Emirates [11], Iran [12], China [13], Greece [14],
Kuwait [15] and South Asia [16]. The EORTC QLQ-BR23
questionnaire was previously translated into Arabic but
was not efficiently validated for use in patients speaking
Moroccan dialect. Indeed, the dialect spoken in Morocco
is very different from the classical Arabic language which
is understood by part of the Moroccan population mainly
educated people.
The objective of this study was to translate and adapt
the original version of the European Organization for
Research and Treatment of Cancer (EORTC) Breast
Cancer-Specific Quality of Life Questionnaire (EORTC
QLQ-BR23) from the English to the Moroccan Arabic
language, to refine its terminology and to adapt it to the
Moroccan culture.Patients and methods
Characteristics of the EORTC QLQ-BR-23original version
The 23 item breast cancer -specific module, the EORTC
QLQ-BR-23 [17], consists of two multi-item functional
scales (body image and sexual functioning), three symp-
tom scales (systemic side effects, breast symptoms, and
arm symptoms), and three single item scales on sexual en-
joyment, future perspectives, and upset by hair loss. The
responses indicate the extent to which patient has experi-
enced symptoms or problems. Each item was scored on a
four point Likert scale (“not at all” [1], to “very much” [4]),
and the time frame was “during the past week”, except for
the sexual items (“during the past four weeks”).
Translation and cultural adaptation of the EORTC
QLQ-BR 23
The EORTC QLQ-BR 23 was translated into local
Moroccan Arabic. We followed the published guidelines
for cross-cultural adaptation of health-related quality of life
measurement [18,19]. The questions in the original ver-
sion of the EORTC QLQ-BR 23 were initially translated
into Moroccan Arabic by two bilingual people. Then it
was reviewed by a committee of professionals composed
by oncologists and epidemiologists, in order to obtain the
first Arabic version. The resulting version of this inter-
mediate Moroccan Arabic version was applied to volun-
teers persons with cancer that agreed to participate and to
present their opinion if the translated version was compre-
hensible; two researchers had to register the comments,
doubts and suggestions. The second Arabic version was
written after this initial assessment. Subsequent back-
translation into English was performed by two other trans-
lators with a good knowledge of English but who were not
familiar with the EORTC QLQ – BR 23. A comparison
with the original version was performed by a committee of
professionals and translators to check whether they con-
tained literal differences. The translation was then reviewed
and adjusted by the committee. In the process of translat-
ing the questionnaire from English into Arabic, several
items were substituted to adapt the terminology to the
local culture : item 39 “Have you felt physically less attract-
ive as a result of your disease or treatment? “ and item 40”
Have you been feeling less feminine as a result of your dis-
ease or treatment?”. A final version of the EORTC QLQ –
BR23 in Moroccan was elaborated. As most of the patients
in our sample were illiterate, the questionnaire was admin-
istered by two interviewers. Their task was to read out the
questions and mark the chosen answers for this category
of patients without providing any input.
The subjects recruitment
Between August and November 2009, subjects were re-
cruited from the two main oncology centers in the country
(National institute of oncology in Rabat and oncology
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tending these two centers are from around the country
(north, center and south). Subjects were eligible if they
were at least 18 years old, had a confirmed diagnosis of
breast cancer and spoke Moroccan Arabic. Ethical ap-
proval was obtained from the ethics committees in the
University Hospital Center Hassan II in Fez- Morocco and
all the subjects were informed of the conditions related to
the study and gave their written, informed consent.
Instruments and procedures
Two questionnaires of the Arabic version of the EORTC
QLQ-BR23 were administered to patients by two differ-
ent interviewers. The order of interviewers was ran-
domly defined.
The participants’ number for the retest were 37. A
third questionnaire was administered three to ten days
later to assess reproducibility. Participants provided
socio-demographic and clinical data and a measure of
pain on a visual analogical scale.
Scoring
The scoring algorithm recommended by the EORTC
[20] was used to analyze participants’ responses to the
QLQ-BR23 questionnaires. In summary, the algorithm
creates an average from component item responses
and then transforms this to a value on a 0–100 scale.
For the functional scales, a higher score corresponds to
better function. For symptom scales, a higher score
corresponds to more frequent and/or more intense
symptoms.
Statistical analysis
Descriptive statistics were generated to evaluate missing
data, score distributions (i.e. mean, range, floor and ceil-
ing effects). The reliability and validity of the EORTC
QLQ-BR23 were examined in the study.
Reliability
The internal consistency of the Moroccan Arabic ver-
sion of the EORTC QLQ – BR23 questionnaire was
assessed for the multi-item questionnaire scales using
Cronbach’s alpha coefficients. A value of 0.70 or greater
was considered as adequate [21]. Test-retest reliability
and inter-observer reliability were estimated by calculat-
ing the intraclass correlation coefficient (ICC) for each
of the score components of the EORTC QLQ – BR23.
Validity
We used multitrait scaling analysis to examine the ex-
tent to which the items of the questionnaire could be
combined into the hypothesized multi-item scales. This
analysis was based on an examination of item-scale cor-
relations for item-convergence and item-discriminance[22]. Evidence of item-convergence was defined as a
correlation of 0.40 or greater between an item and its
own scale. item-discriminance was satisfied if each item
has a substantially higher correlation with its hypothe-
sized scale than with scales measuring other concepts.Acceptability
The acceptability of the EORTC QLQ – BR23 was
assessed with the response rate, percentage of missing
Data and time required to complete the questionnaire. A
P value of <0.05 was considered statistically significant.
Data analysis was performed using SPSS 17.Results
In total, the questionnaire was administered to 105 pa-
tients, 44 were recruited in Rabat and 61 in Casablanca.
The mean age was 48 (standard deviation 16) years. The
majority were married (62.9%); illiterate (60%) and lived
in urban areas (68.6%). The Socio-demographic charac-
teristics of the study sample appear in Table 1.
The average time to complete the EORTC QLQ-BR23
was 15 min. Missing data rate for items varied from 0.0%
to 49.5%. 83% of items didn’t have missing responses.
Data on central tendency and variability of EORTC
QLQ-BR23 scale are presented in Table 2. The scores
for different scales ranged from 34.0 to 77.8. “Systemic
therapy side effects” scale had the lower score (median
57.14). High floor effect was observed for the “Future
perspective “scale and the higher ceiling effect was ob-
served for the “Body image” (Table 2).
Data on reliability of EORTC QLQ-BR23 scale are pre-
sented in Table 3. Throughout the instrument, only one
scale (breast symptoms) did not meet the 0.70 internal
consistency criterion, and another (arm symptoms) was
borderline (α = 0.68).
The ICC between two interviewers, ranged from 0.24
for “Sexual enjoyment” to 0.87 for “Systemic therapy side
effects “.
We collected test/retest data from 37 patients among
whom the questionnaire was administered twice (during
the baseline visit and on average 5 days later). Test-
retest reliability was assessed using the ICC, which
ranged from 0.68 for “Sexual enjoyment” and “Systemic
therapy side effects “to 0.85 for “Body image”.
Results for multitrait scaling analysis are shown in
Table 4. The breast symptom scale exhibited moderate
item-convergence with only two out of 4 items (50.0%) ex-
ceeding the criterion of 0.40 for the correlation coefficient
(r : 0.04-0.8). The body image and Arm symptoms scales
exhibited 100% item-convergence (r: 0.77-0.83 and 0.57-
0.84, respectively) and 100% item-discriminance (r : 0.06-
0.53 and 0.02-0.52, respectively).
Table 1 Sociodemographic characteristics of 105 patients























Âge mean (SD) 48.1 (10.5)
Third assessment (test-retest) 37 35.2
SD: Standard deviation.
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The EORTC QLQ-BR23 instruments have been trans-
lated into local Moroccan Arabic according to proce-
dures documented elsewhere [18,19]. The present study
aimed to assess the reliability and validity of this transla-
tion for use in Morocco. This evaluation of the measure-
ment properties of the Moroccan Arabic version of theTable 2 Central tendency, variability of the EORTC QLQ-BR23
N Median Mean
Body image 105 83.33 77.54
Sexual functioning 66 66.66 61.11
Sexual enjoyment 53 66.67 58.49
Future perspective 105 66.67 46.98
Systemic therapy side effects 105 57.14 59.86
Breast symptoms 105 83.33 77.86
Arm symptoms 105 77.78 0.00
Upset by hair loss 50 68.94 34.00
aPercentage of the lowest modality.
bPercentage of the highest modality.EORTC QLQ-BR23 shows that it is a reliable and valid
measure of QoL in Moroccan patients with breast cancer.
In the translation stage, we followed the international
guidelines for cross-cultural adaptation of health-related
quality of life measures [18,19]. We then supplemented a
pilot test in Moroccan patients who were asked to identify
words and sentence structures that were problematic for
the target population. Next, a conceptual adaptation in the
final version was performed: Certain expressions in the
original version of the EORTC QLQ-BR23 needed modifi-
cation in the Moroccan version of the EORTC QLQ-
BR23. They mainly concerned the item 39 “Have you felt
physically less attractive as a result of your disease or treat-
ment? “ and item 40” Have you been feeling less feminine
as a result of your disease or treatment?”. The Arabic dia-
lect translation of the phrases “ less attractive “ and “ less
feminine” doesn’t exist, so we have changed the first one
into “your look isn’t appreciated anymore”, while we trans-
lated the second one into classical Arabic.
The necessary number of subjects used was calculated
based on the reliability curve of Streiner [23] and was con-
sidered sufficient to evaluate psychometric properties. The
mean time required for conducting the interviews was 15
min, the same time reported in studies from other coun-
tries [24-26]. Time between test and retest was five days
on average. Streiner and Norman indicated that expert
opinions regarding the appropriate interval varies from
one hour to one year, depending on the task, but generally,
a retest interval of 2 to 14 days is usually used [23].
The internal consistency coefficients of most scales in
the EORTC QLQ-BR23 were also satisfactory. This was
confirmed by the Cronbach’s alpha values that exceeded
0.70 for all scales except the arm symptoms and breast
symptoms scales. The highest value of Cronbach’s alpha
for the EORTC QLQ-BR23 was found for sexual function-
ing (alpha: 0.76), a finding previously reported among
Iranian and Western women [27]. This suggests that sex-
related determinants of QoL are perceived similarly by pa-
tients with different cultural backgrounds.scale









Table 3 Internal consistency and reliability of the EORTC
QLQ-BR23
Cronbach’s α Reliability CCI
Inter-observer Test-retest
Body image 0,76 0,76 0,85
Sexual functioning 0,76 0,5 0,79
Sexual enjoyment - 0,24 0,68




Breast symptoms 0,5 0,80 0,79
Arm symptoms 0,63 0,85 0,75
Upset by hair loss - 0,80 0,79
El Fakir et al. BMC Research Notes 2014, 7:53 Page 5 of 6
http://www.biomedcentral.com/1756-0500/7/53The test/retest correlations of the EORTC QLQ-BR23
were also high in most scale/single items. Because of the
small sample size, the results of test/retest of this study,
though mostly satisfactory, might be subject to errors
and should be read with caution.
Construct validity was assessed by testing convergent
and discriminant validity of items. The body imageand
sexual functioning scales exhibited strong psychometric
properties with satisfactory results for multitrait scaling.
The Breast symptoms scale evidenced moderate item-
convergence, which is consistent with previous studies
on Greek patients with breast cancer [14]. This result
for multitrait scaling confirmed the hypothesized scale
structure, implying that the translation of the items and
the response choices are appropriate and that scale
scores derived from the Moroccan Arabic version could
contribute to cross-cultural comparisons.
Because of the high frequency of illiteracy among par-
ticipants, an interviewer had administered the question-
naire for most patients. Unlike northern countries, the
questionnaire could not be used as an auto-administered
questionnaire except for a minority of Moroccan popula-
tion. Another limitation related to illiteracy among par-





Body image 0,77-0,83, 100 0.06-0.53, 100
Sexual functioning 0,89-0,91, 100 0.09-0.35, 100
Systemic therapy side effects 0,48-0,66, 100 0.01-0.37, 96.42
Breast symptoms 0,04-0.8, 50 0.00-0.89, 0.75
Arm symptoms 0,57-0,84, 100 0.02-0.52, 100
*Number of item-scale correlations greater than 0.40 /total number of
item-scale correlations.
**Number of correlations of items with own scales significantly higher than
correlations with other scale/total number of correlations.affected especially those related with their sexual life
which’s a kind of taboo for them.
A limitation of the study is that responsiveness over
time was not performed. We would recommend that
additional studies be carried out with patients under ac-
tive treatment in order to document the responsiveness.
Despite the fact that Arabic language is commonly
spoken across the country, there are some other regional
languages such as “Tarifit”, “Tamazight” and “Tachelhit”
that are more popular in some Moroccan regions. But,
the majority of these people speak also Arabic. Further
validation should be specifically performed in these re-
gions because inclusion in these patient groups in local
or national clinical studies is essential.
Conclusion
Based on the findings of this study, the Moroccan Arabic
version of the QLQ-BR23 questionnaire has acceptable
reliability and validity, which are comparable to those re-
ported in other languages. In addition, the questionnaire
could be used in clinical trials that evaluate the impact
of specific interventions on the QoL of Moroccan pa-
tients with breast cancer.
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